Nuvation Bio (NUVB) Competitors

$3.32
-0.09 (-2.64%)
(As of 05/17/2024 ET)

NUVB vs. NRIX, BCYC, ANAB, MLYS, DNTH, WVE, PAHC, CVAC, SVRA, and SLN

Should you be buying Nuvation Bio stock or one of its competitors? The main competitors of Nuvation Bio include Nurix Therapeutics (NRIX), Bicycle Therapeutics (BCYC), AnaptysBio (ANAB), Mineralys Therapeutics (MLYS), Dianthus Therapeutics (DNTH), Wave Life Sciences (WVE), Phibro Animal Health (PAHC), CureVac (CVAC), Savara (SVRA), and Silence Therapeutics (SLN). These companies are all part of the "pharmaceutical preparations" industry.

Nuvation Bio vs.

Nuvation Bio (NYSE:NUVB) and Nurix Therapeutics (NASDAQ:NRIX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, valuation, dividends, analyst recommendations, profitability, media sentiment, institutional ownership, community ranking and earnings.

Nuvation Bio has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -178.93%. Nuvation Bio's return on equity of -11.31% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation BioN/A -11.31% -10.99%
Nurix Therapeutics -178.93%-67.08%-43.62%

Nuvation Bio currently has a consensus price target of $6.60, indicating a potential upside of 98.80%. Nurix Therapeutics has a consensus price target of $21.88, indicating a potential upside of 31.86%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nurix Therapeutics
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88

61.7% of Nuvation Bio shares are owned by institutional investors. 36.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 7.2% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Nuvation Bio has higher earnings, but lower revenue than Nurix Therapeutics. Nuvation Bio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation BioN/AN/A-$75.80M-$0.31-10.71
Nurix Therapeutics$76.99M10.59-$143.95M-$2.66-6.24

Nurix Therapeutics received 19 more outperform votes than Nuvation Bio when rated by MarketBeat users. However, 72.09% of users gave Nuvation Bio an outperform vote while only 71.43% of users gave Nurix Therapeutics an outperform vote.

CompanyUnderperformOutperform
Nuvation BioOutperform Votes
31
72.09%
Underperform Votes
12
27.91%
Nurix TherapeuticsOutperform Votes
50
71.43%
Underperform Votes
20
28.57%

In the previous week, Nurix Therapeutics had 5 more articles in the media than Nuvation Bio. MarketBeat recorded 18 mentions for Nurix Therapeutics and 13 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.62 beat Nurix Therapeutics' score of 0.18 indicating that Nuvation Bio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
3 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nurix Therapeutics
2 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

Nuvation Bio has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 2.1, suggesting that its stock price is 110% more volatile than the S&P 500.

Summary

Nuvation Bio beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUVB vs. The Competition

MetricNuvation BioPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$723.91M$6.80B$5.24B$18.14B
Dividend YieldN/A2.72%44.24%3.44%
P/E Ratio-10.719.0094.4921.91
Price / SalesN/A284.792,373.7210.59
Price / CashN/A34.4236.7919.24
Price / Book1.225.795.496.00
Net Income-$75.80M$138.82M$105.95M$966.17M
7 Day Performance2.15%1.45%1.42%1.85%
1 Month Performance28.68%4.81%4.96%6.59%
1 Year Performance103.68%-3.83%7.84%23.69%

Nuvation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRIX
Nurix Therapeutics
2.0696 of 5 stars
$14.16
+7.1%
$21.33
+50.7%
+70.3%$695.96M$76.99M-5.32284Analyst Forecast
News Coverage
BCYC
Bicycle Therapeutics
2.4452 of 5 stars
$23.08
-0.9%
$46.86
+103.0%
-8.2%$693.32M$26.98M-5.19284Short Interest ↓
ANAB
AnaptysBio
2.317 of 5 stars
$25.68
-0.3%
$46.22
+80.0%
+32.4%$701.58M$17.16M-4.22117Positive News
MLYS
Mineralys Therapeutics
2.6134 of 5 stars
$14.17
+3.1%
$33.50
+136.4%
-18.0%$703.26MN/A-7.0928High Trading Volume
DNTH
Dianthus Therapeutics
1.226 of 5 stars
$24.04
+0.5%
$42.40
+76.4%
N/A$705.57M$2.83M0.0053Analyst Forecast
Short Interest ↑
Analyst Revision
News Coverage
WVE
Wave Life Sciences
4.5791 of 5 stars
$5.79
+0.7%
$10.14
+75.2%
+75.8%$708.23M$113.31M-10.53266Analyst Forecast
PAHC
Phibro Animal Health
4.0749 of 5 stars
$16.77
+1.9%
$15.33
-8.6%
+32.7%$679.19M$977.90M46.581,920
CVAC
CureVac
3.5158 of 5 stars
$2.99
+1.7%
$8.33
+178.7%
-60.2%$669.40M$58.18M0.001,172Gap Up
SVRA
Savara
1.276 of 5 stars
$5.26
+6.3%
$8.20
+55.9%
+75.0%$726.83MN/A-15.94N/AAnalyst Forecast
Analyst Revision
News Coverage
SLN
Silence Therapeutics
2.6573 of 5 stars
$22.19
+1.3%
$57.25
+158.0%
+281.4%$664.15M$31.55M-15.20109Analyst Forecast
News Coverage

Related Companies and Tools

This page (NYSE:NUVB) was last updated on 5/19/2024 by MarketBeat.com Staff

From Our Partners